Literature DB >> 2445283

Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.

D A Enria1, A M Briggiler, S Levis, D Vallejos, J I Maiztegui, P G Canonico.   

Abstract

Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution. Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers. The average time of death was delayed. A reversible anemia was the only adverse effect observed. From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed. The possible beneficial effect of ribavirin during the initial days of AHF is discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445283     DOI: 10.1016/0166-3542(87)90017-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  19 in total

1.  Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence.

Authors:  P Seiler; B M Senn; P Klenerman; U Kalinke; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 2.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

3.  An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses.

Authors:  Gustavo Helguera; Stephanie Jemielity; Jonathan Abraham; Sandra M Cordo; M Guadalupe Martinez; José A Rodríguez; Carlos Bregni; Jinyize J Wang; Michael Farzan; Manuel L Penichet; Nélida A Candurra; Hyeryun Choe
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Toll-like receptor 2-mediated innate immune responses against Junín virus in mice lead to antiviral adaptive immune responses during systemic infection and do not affect viral replication in the brain.

Authors:  Christian D Cuevas; Susan R Ross
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

5.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

Review 6.  Drug discovery technologies and strategies for Machupo virus and other New World arenaviruses.

Authors:  Sheli R Radoshitzky; Jens H Kuhn; Fabian de Kok-Mercado; Peter B Jahrling; Sina Bavari
Journal:  Expert Opin Drug Discov       Date:  2012-05-19       Impact factor: 6.098

7.  Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.

Authors:  M Gupta; S Mahanty; M Bray; R Ahmed; P E Rollin
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage.

Authors:  Maya F Kotturi; Jason Botten; Matt Maybeno; John Sidney; Jean Glenn; Huynh-Hoa Bui; Carla Oseroff; Shane Crotty; Bjoern Peters; Howard Grey; Daniel M Altmann; Michael J Buchmeier; Alessandro Sette
Journal:  Immunome Res       Date:  2010-05-17

9.  Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog.

Authors:  Brian B Gowen; Min-Hui Wong; Deanna Larson; Wei Ye; Kie-Hoon Jung; Eric J Sefing; Ramona Skirpstunas; Donald F Smee; John D Morrey; Stewart W Schneller
Journal:  PLoS One       Date:  2010-09-16       Impact factor: 3.240

10.  Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs.

Authors:  Nadezhda E Yun; Nathaniel S Linde; Natallia Dziuba; Michele A Zacks; Jeanon N Smith; Jennifer K Smith; Judy F Aronson; Olga V Chumakova; Heather M Lander; Clarence J Peters; Slobodan Paessler
Journal:  Am J Trop Med Hyg       Date:  2008-08       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.